Table 1. Baseline characteristics of the included trials.

Author/year	Angelo Naselli/2012				Harry W. Herr/2014				Kohei Kobatake/2015			Stănescu F/2014			Bogdan Geavlete/2011			Ma Tianji/2015
	Total	WLI	NBI		Total	WLI	NBI		Total	WLI	NBI	Total	WLI	NBI	Total	WLI	NBI	Total	WLI	NBI
Design	A prospective randomized trial				A prospective randomized trial				A retrospective study			A prospective study			A prospective randomized trial			A prospective randomized trial
Sex, n	148	72	76		254	127	127		135	78	57				220	110	110	178	92	86
Male	29	17	12		183	95	88		110	62	48				161	82	79	148	79	69
Female	119	55	64		71	32	39		25	16	9				59	28	31	30	13	17
Age, median (range)					68(42-99) 7(36-93)					73	75	64.8 (33-86) 5.2 (32-87)			64.5(30-83) 3.7(31-84)
Mean±SD	71.6±12.470.8±10.3																		62±8	63±9
Clinical status									135	78	57
Recurrent	65	28	37						78	45	33
Newly diagnosed	83	44	39		254	127	127		57	33	24	ALL			ALL
No. of tumors, n					254	127	127		135	78	57				220	110	110	178	92	86
Single	76	39	37		34	15	19		59	35	24				73	38	35	104	54	50
Multiple	72	33	39		220	112	108		76	43	33	NA			147	72	75	74	38	36
Grade									135	78	57
								1	11	8	3
Low		41	39					2	87	51	36	NA				NA
High		31	37		254	127	127	3	37	19	18
Stage					254	127	127		135	78	57				179	90	89
T0
Ta	110	52	58		161	81	80		106	61	45				50	26	24
Tis									8	5	3
T1	38	20	18		93	46	47		21	12	9				129	64	65
Tumor size					254	127	127		135	78	57							178	92	86
				<1-2cm	19	9	10
≤3 cm	108	53	55	2-5cm	194	97	97		122	69	53							128	63	65
≥3 cm	40	19	21	>5cm	41	21	20		13	9	4	ALL			ALL			50	29	21
Adjuvant intravesical therapy					6-wk induction				NA
No therapy	91	49	42									All immediate instillation: doxorubicin or epirubicin; Re-TUR: BCG(1-yr)			ALL			All immediate instillation: Pirarubicin; The intermediate and high risk: Pirarubicin(1-yr)
BCG	43	19	24		254	127	127
Mitomycin	14	4	10
Pirarubicin
follow-up	11 mo (range 2–19 mo)				A minimum of 2 yr					1 yr
Exclusion criteria	invasive BCa; without followup; absence pathologic				NA				Received post-operative intravesical injections of			muscle-invasive bladder cancer			muscle-invasive bladder cancer			Muscle-invasive bladder cancer, No received
Operative process	WLI-ETUR: WLI cystoscopy—WLI-ETUR;				WEI-ETUR: WLI cystoscopy—WLI-ETUR; NBI-ETUR: WLI cystoscopy–NBI cystoscopy–NBI-ETUR-WLI and NBI cystoscopy				WLI-ETUR: WLI cystoscopy—WLI-ETUR; NBI-ETUR: WLI cystoscopy—NBI cystoscopy—NBI-ETUR			WIL-ETUR: WLI cystoscopy—WLI-ETUR; NBI-BPV: WLI cystoscopy–NBI cystoscopy–WLI and NBI-BPV			WIL-ETUR: WLI cystoscopy—WLI-ETUR; NBI-BPV: WLI cystoscopy–NBI cystoscopy–WLI and NBI-BPV			WLI-ETUR: WLI cystoscopy—WIL-ETUR; NBI cystoscopy–WLI and NBI-HLR